Notably, we observed a similar improvement in anti-tumor efficacy by Snx9 KO when OTI cells were transferred to (immunodeficient) NSG mice with MC38-OVA tumors (Fig. 4j, Supplementary Fig. 9g). This evidence concerns the gene SNX9 and neoplasm.